{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:49:41Z","timestamp":1791233381535,"version":"4.1.0"},"reference-count":45,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Context<\/jats:title><jats:p>Tyrosine kinase inhibitors (TKIs) can be used to treat locally unresectable or distantly metastatic pheochromocytomas\/paragangliomas (PPGLs), such as sunitinib, according to the National Comprehensive Cancer Network guidelines in 2022. However, the precise effect of different TKIs in metastatic PPGLs is still unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The aim of this meta-analysis is to assess the efficacy and safety of TKIs in metastatic PPGLs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The PubMed, Cochrane Library, Scopus, Clinical Trial, and Embase databases were searched by synonyms of 48 TKIs and metastatic PPGLs from inception up to August 2022. Outcomes were tumor response or survival data and the incidence of adverse events (AEs) after treatment. The MIONRS scale and the JBI's tools for case series were used for interventional and observational studies to assess risk of bias, respectively. The combined effects with fixed- or random-effect models, the combined median with the weighted median of medians method and their 95% CIs were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 7 studies with 160 patients were included. Tumor responses in metastatic PPGLs in 5 studies with available data showed the pooled proportion of partial response (PR), stable disease, and disease control rate (DCR) of, respectively, 0.320 (95% CI 0.155-0.486), 0.520 (95% CI 0.409-0.630), and 0.856 (95% CI 0.734-0.979). The combined median progressive-free survival in 6 studies was 8.9 months (95% CI 4.1-13.5) and the proportion of those who discontinued due to AEs in 5 studies was 0.143 (95% CI 0.077-0.209).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This meta-analysis suggests that patients with metastatic PPGLs can benefit from TKI therapy with PR and DCR up to more than 30% and 80%. However, because of restricted studies, larger clinical trials should be performed in the future.<\/jats:p><\/jats:sec>","DOI":"10.1210\/clinem\/dgac657","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T17:28:43Z","timestamp":1668619723000},"page":"755-766","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients with Metastatic Pheochromocytomas\/Paragangliomas"],"prefix":"10.1210","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2639-6934","authenticated-orcid":false,"given":"Yue","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Health Commission of the People's Republic of China, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing 100730 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunying","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Health Commission of the People's Republic of China, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing 100730 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5234-752X","authenticated-orcid":false,"given":"Dingding","family":"Zhang","sequence":"additional","affiliation":[{"name":"Medical Research Center, State Key laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing 100730 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1418-1012","authenticated-orcid":false,"given":"Anli","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Health Commission of the People's Republic of China, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing 100730 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"issue":"3","key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12022-017-9484-5","article-title":"Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours","volume":"28","author":"Lam","year":"2017","journal-title":"Endocr Pathol"},{"issue":"3","key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s12020-011-9545-3","article-title":"Pheochromocytomas and paragangliomas: assessment of malignant potential","volume":"40","author":"Korevaar","year":"2011","journal-title":"Endocrine"},{"issue":"6","key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/jso.23297","article-title":"Malignant pheochromocytoma and paraganglioma: a population level analysis of long-term survival over two decades","volume":"107","author":"Goffredo","year":"2013","journal-title":"J Surg Oncol"},{"issue":"3","key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4158\/EP15725.OR","article-title":"Characteristics and outcomes of metastatic SDHB and sporadic pheochromocytoma\/paraganglioma: an national institutes of health study","volume":"22","author":"Turkova","year":"2016","journal-title":"Endocr Pract"},{"key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"587769","DOI":"10.3389\/fendo.2020.587769","article-title":"Recent advances in histopathological and molecular diagnosis in pheochromocytoma and paraganglioma: challenges for predicting metastasis in individual patients","volume":"11","author":"Yamazaki","year":"2020","journal-title":"Front Endocrinol"},{"issue":"17","key":"2023021518395719900_","first-page":"5615","article-title":"Mutations in the SDHB gene are associated with extra-adrenal and\/or malignant phaeochromocytomas","volume":"63","author":"Gimenez-Roqueplo","year":"2003","journal-title":"Cancer Res"},{"issue":"31","key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1200\/JCO.2011.34.6353","article-title":"Metastatic pheochromocytoma\/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations","volume":"29","author":"King","year":"2011","journal-title":"J Clin Oncol"},{"issue":"10","key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1210\/jc.2007-0709","article-title":"Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas","volume":"92","author":"Amar","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrc3648","article-title":"Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity","volume":"14","author":"Dahia","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1210\/jc.2008-2504","article-title":"The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas","volume":"94","author":"Burnichon","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1371\/journal.pgen.0010008","article-title":"A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas","volume":"1","author":"Dahia","year":"2005","journal-title":"PLoS Genet"},{"issue":"9","key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1093\/hmg\/ddt639","article-title":"Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas","volume":"23","author":"Castro-Vega","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"11","key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1530\/ERC-20-0205","article-title":"HIF2\u03b1 supports pro-metastatic behavior in pheochromocytomas\/paragangliomas","volume":"27","author":"Bechmann","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/B978-0-12-411512-5.00014-2","article-title":"Role of hypoxia and HIF2\u03b1 in development of the sympathoadrenal cell lineage and chromaffin cell tumors with distinct catecholamine phenotypic features","volume":"68","author":"Richter","year":"2013","journal-title":"Adv Pharmacol"},{"issue":"12","key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1530\/ERC-16-0231","article-title":"Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome","volume":"23","author":"D\u00e4rr","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"2023021518395719900_","first-page":"334","article-title":"Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma","volume":"52","author":"Forrer","year":"2008","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"2","key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/snuc\/2002.31025","article-title":"Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience","volume":"32","author":"Valkema","year":"2002","journal-title":"Semin Nucl Med"},{"issue":"10","key":"2023021518395719900_","first-page":"1599","article-title":"Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma","volume":"47","author":"van Essen","year":"2006","journal-title":"J Nucl Med"},{"issue":"5","key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity (131)I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J Nucl Med"},{"issue":"5","key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/cen.12542","article-title":"Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis","volume":"81","author":"Niemeijer","year":"2014","journal-title":"Clin Endocrinol"},{"issue":"8","key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/cncr.23812","article-title":"Treatment of malignant pheochromocytoma\/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients","volume":"113","author":"Huang","year":"2008","journal-title":"Cancer"},{"issue":"5","key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s10571-018-0579-4","article-title":"Continued tumor reduction of metastatic pheochromocytoma\/paraganglioma harboring succinate dehydrogenase subunit B mutations with cyclical chemotherapy","volume":"38","author":"Jawed","year":"2018","journal-title":"Cell Mol Neurobiol"},{"key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3389\/fendo.2020.00061","article-title":"Temozolomide is a potential therapeutic tool for patients with metastatic pheochromocytoma\/paraganglioma-case report and review of the literature","volume":"11","author":"Tong","year":"2020","journal-title":"Front Endocrinol"},{"issue":"3","key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1530\/EJE-14-0113","article-title":"Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma","volume":"171","author":"Baudin","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1053\/j.semnuclmed.2016.01.011","article-title":"I-131 Metaiodobenzylguanidine therapy of pheochromocytoma and paraganglioma","volume":"46","author":"Carrasquillo","year":"2016","journal-title":"Semin Nucl Med"},{"issue":"7","key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","article-title":"Neuroendocrine and adrenal tumors, version 1.2022, NCCN clinical practice guidelines in oncology","volume":"19","author":"Shah","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/modpathol.2013.233","article-title":"Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas","volume":"27","author":"Cassol","year":"2014","journal-title":"Mod Pathol"},{"issue":"3","key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1159\/000510003","article-title":"Durable response to pazopanib in recurrent metastatic carotid body paraganglioma","volume":"13","author":"Alshamsan","year":"2020","journal-title":"Case Rep Oncol"},{"issue":"6","key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/548.6526","article-title":"Metastatic paraganglioma and treatment with sunitinib: a case report","volume":"96","author":"Cirillo","year":"2010","journal-title":"Tumori"},{"key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"594264","DOI":"10.3389\/fendo.2020.594264","article-title":"A durable response with the combination of nivolumab and cabozantinib in a patient with metastatic paraganglioma: a case report and review of the current literature","volume":"11","author":"Economides","year":"2020","journal-title":"Front Endocrinol"},{"key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"e13523","DOI":"10.1200\/jco.2012.30.15_suppl.e13523","article-title":"Sorafenib in the treatment of metastatic paraganglioma: a case report.","volume":"30","author":"Gunaldi","year":"2012","journal-title":"J Clin Oncol"},{"key":"2023021518395719900_","author":"Zhou"},{"issue":"2","key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer)"},{"issue":"(Suppl 1)","key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"122s","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"issue":"9","key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"issue":"10","key":"2023021518395719900_","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"key":"2023021518395719900_","author":"McGrath","year":"2020"},{"issue":"11","key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1210\/jc.2012-2356","article-title":"Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas","volume":"97","author":"Ayala-Ramirez","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023021518395719900_","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvac044","article-title":"Lenvatinib as a therapeutic option in unresectable metastatic pheochromocytoma and paragangliomas","volume":"6","author":"Hassan Nelson","year":"2022","journal-title":"J Endocr Soc"},{"issue":"12","key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41416-019-0474-x","article-title":"A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. Article","volume":"120","author":"O\u2019Kane","year":"2019","journal-title":"Br J Cancer"},{"key":"2023021518395719900_","first-page":"S621","article-title":"First International Randomized Study in Malignant Progressive Pheochromocytoma and Paragangliomas (FIRSTMAPPP): an academic double-blind trial investigating sunitinib","author":"Baudin","year":"2021"},{"key":"2023021518395719900_","first-page":"150","article-title":"Treatment with sunitinib in advanced malignant pheochromocytoma\/paraganglioma","author":"Prinzi","year":"2019"},{"key":"2023021518395719900_","first-page":"25","article-title":"A phase 2 study to evaluate the effects of cabozantinib in patients with unresectable metastatic pheochromocytomas and paragangliomas","author":"Jimenez","year":"2018"},{"issue":"1","key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1590\/2359-3997000000217","article-title":"Sunitinib in the therapy of malignant paragangliomas: report on the efficacy in a SDHB mutation carrier and review of the literature","volume":"61","author":"Canu","year":"2017","journal-title":"Arch Endocrinol Metab"},{"issue":"2","key":"2023021518395719900_","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac657\/47794245\/dgac657.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/3\/755\/49201239\/dgac657.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/3\/755\/49201239\/dgac657.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,12]],"date-time":"2023-03-12T09:21:18Z","timestamp":1678612878000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/3\/755\/6831422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":45,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,11,16]]},"published-print":{"date-parts":[[2023,2,15]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac657","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2022,11,16]]}}}